Unlearn is the only company using AI to create Digital Twins to populate Intelligent Control Arms in clinical studies. By leveraging historical datasets and disease-specific machine-learning models, Unlearn generates virtual placebo patients, created from actual patient baseline data in clinical studies. This novel approach increases trial power and confidence, accelerates trial timelines, and enables patient level insights. Unlearn was founded in 2017 by a team of world-class machine learning scientists who shared a vision of using machine learning to streamline clinical trials. Unlearn has received a total of $20M in funding, most recently in a Series A extension lead by Eisai, Epic Ventures, and Alumni Ventures. Unlearn has authored a peer-reviewed publication in Nature, and is partnering with one of the world’s leading pharma companies. Digital Twins are currently part of an ongoing pivotal Alzheimer’s Disease trial. In 2020, Unlearn was named a CB Insights Digital Health 150 Company, and the winner of the Innovation Showcase at CNS Summit. Unlearn continues to have discussions with regulators, industry leaders, and other key stakeholders, and is seeking partners to help drive innovation in clinical research using AI.Something looks off?